## 4 Conclusions  
We collected a series of 146 patients with chronic hepatitis B who underwent liver needle biopsy (50.9%) or surgery for tumor resection (49.1% Table 1). Thirty-four (23.3%) patients had received anti-HBV therapy at the time of liver histology and ARFI analysis. The AUROC for mean ARFI (0.796, Figure 2) to detect liver cirrhosis (Metavir F4) in anti-HBV treated patients. When the cut-off of the mean ARFI was set to 1.420 m/sec, the sensitivity was 0.786 and the specificity was 0.750 (Table 2). To the best of our knowledge, the correlation between histology and ARFI in patients receiving anti-HBV treatment was quite rare and was generally in HIV/HBV dual-infected patients [29; 30]. \begin{table}
\begin{tabular}{c c c c c c c c c c c} \hline \hline \multirow{2}{*}{**Case**} & \multirow{2}{*}{**Age**} & \multirow{2}{*}{**Sex**} & \multirow{2}{*}{**HCC**} & \multirow{2}{*}{**ALT**} & \multirow{2}{*}{**Durg**} & \multirow{2}{*}{**Treatment**} & \multirow{2}{*}{**METAVIR**} & \multirow{2}{*}{**\# Mean of**} & \multirow{2}{*}{**Predicted**} & **\multirow{2}{*}{**\(\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{1}}}}}}}}}}}}\) } \\  & & & & & & & & & & & \\ \hline  & & & & & & & & & & \\ T1 & 55.7 & M & 1 & 48 & ETV & 2 & 2 & 1.17 & 2 & equal \\ T2 & 48.3 & M & 0 & 335 & Pegasy & 5 & 2 & 1.4 & 3 & higher \\ T3 & 52.8 & M & 0 & 103 & ETV & 6 & 2 & 1.3 & 2 & equal \\ T4 & 47.3 & M & 0 & 50 & ETV & 12 & 3 & 1.5 & 4 & higher \\ T5 & 30.2 & M & 0 & 46 & ETV & 12 & 4 & 1.84 & 4 & equal \\ T6 & 50.3 & M & 0 & 100 & IDF & 13 & 3 & 1.41 & 3 & equal \\ T7 & 45.2 & M & 0 & 39 & ETV & 14 & 4 & 1.59 & 4 & equal \\ T8 & 71.3 & F & 0 & 172 & ETV & 18 & 4 & 3.96 & 4 & equal \\ T9 & 52.1 & M & 0 & 23 & ETV & 19 & 3 & 1.77 & 4 & higher \\ T10 & 64.1 & F & 1 & 23 & ETV & 21 & 3 & 1.38 & 3 & equal \\ T11 & 55.3 & M & 1 & 45 & ETV & 22 & 4 & 1.73 & 4 & equal \\ T12 & 53.0 & M & 1 & 19 & ADVTBV & 26 & 4 & 1.59 & 4 & equal \\ T13 & 57.1 & M & 1 & 42 & ETV & 28 & 3 & 1.15 & 1 & lower \\ T14 & 60.9 & M & 1 & 16 & ETV & 29 & 4 & 1.93 & 4 & equal \\ T15 & 65.6 & F & 0 & 10 & ETV & 31 & 3 & 1.49 & 4 & higher \\ T16 & 64.0 & F & 1 & 27 & IDF & 31 & 4 & 2.65 & 4 & equal \\ T17 & 45.9 & M & 0 & 26 & ETV & 31 & 4 & 2.12 & 4 & equal \\ T18 & 51.5 & M & 1 & 26 & ETV & 32 & 3 & 1.29 & 3 & lower \\ T19 & 41.3 & M & 1 & 26 & ETV & 32 & 4 & 1.43 & 2 & lower \\ T20 & 49.3 & M & 0 & 35 & IDF & 36 & 3 & 1.47 & 1 & lower \\ T21 & 68.4 & F & 1 & 19 & IDF & 36 & 4 & 1.16 & 2 & lower \\ T22 & 45.4 & M & 1 & 45 & IDF & 36 & 3 & 1.29 & 3 & equal \\ T23 & 45.0 & M & 0 & 316 & IDF & 37 & 4 & 1.9 & 4 & equal \\ T24 & 68.1 & M & 0 & 16 & ETV & 39 & 1 & 0.995 & 0 & lower \\ T25 & 59.7 & M & 0 & 34 & IDF & 39 & 3 & 1.36 & 3 & equal \\ T26 & 42.0 & M & 0 & 19 & ETV & 41 & 3 & 1.105 & 1 & lower \\ T27 & 60.3 & M & 1 & 50 & IDF & 44 & 2 & 1.12 & 1 & lower \\ T28 & 63.0 & F & 1 & 16 & IDF & 48 & 2 & 0.995 & 0 & lower \\ T29 & 73.9 & M & 1 & 13 & IDF & 52 & 4 & 1.52 & 4 & equal \\ T30 & 62.7 & M & 1 & 26 & ETV & 55 & 3 & 1.23 & 2 & lower \\ T31 & 38.5 & M & 1 & 26 & ETV & 58 & 4 & 1.18 & 1 & lower \\ T32 & 50.4 & M & 1 & 24 & ETV & 60 & 1 & 1.19 & 1 & equal \\ T33 & 63.7 & M & 1 & 21 & ETV & 68 & 3 & 1.115 & 1 & lower \\ T34 & 69.5 & M & 1 & 68 & ETV & 71 & 4 & 1.435 & 3 & lower \\ \hline \hline \end{tabular}  
* 18: possible hypoglycemic agent related toxic hepatitis; T23: poor compliance. Abbreviation: ADV (adver); ETV (entexcity); TBV (telivoludine); TDF (tenofovir); # [PERSON]’s rho correlation coefficients\(-\)0.428, \(p\) \(<\) 0.012. \(\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{}}}}}}}}}}}}}}\) The cut-off values for prediction of Metavir fibrosis scores 0, 1, 2, 3, 4 are 1.105, 1.218, 1.343, 1.478 m/sec, respectively.
* Chi-square test of goodness of fit and independence \(p\) = 0.0012.  
\end{table} 
Table 3: Correlation of ARFI, Metavir score, and treatment duration.